Review

Are Static Spacers Superior to Articulated Spacers in the Staged Treatment of Infected Primary Knee Arthroplasty? A Systematic Review and Meta-Analysis

Michele Fiore 1, Andrea Sambri 1,*, Matteo Filippini 1, Lorenzo Morante 1, Claudio Giannini 1, Azzurra Paolucci 1, Claudia Rondinella 1, Renato Zunarelli 1, Pierluigi Viale 2 and Massimiliano De Paolis 1

1 Orthopaedics and Traumatology Unit, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy
2 Infectious Disease Unit, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy
* Correspondence: andrea_sambri@libero.it

Abstract: In the treatment of knee periprosthetic joint infection with a two-stage protocol, static spacers allow for the local delivery of high doses of antibiotics and help to preserve soft tissue tension. Articulated spacers were introduced to better preserve flexion after the reimplantation. The aim of this systematic review is to provide a comprehensive data collection of the results of these different spacers. An in-depth search on the main clinical databases was performed concerning the studies reporting data on the topic. A total of 87 studies and 4250 spacers were included. No significant differences were found both in pooling data analysis and meta-analysis of comparative studies about infection recurrences, complications, and clinical scores. Mean active knee flexion at last follow-up after total knee reimplantation was found to be significantly higher using articulated spacers (91.6° ± 7° for static spacers vs. 100.3° ± 9.9° for articulated spacers; p < 0.001). Meta-analysis also recognized this strong significant difference (p < 0.001). This review has confirmed that articulated spacers do not appear to be inferior to static spacers regarding all clinical outcomes, while they are superior in terms of active flexion. However, the low quality of the studies and the risk for selection bias with complex patients preferentially treated with static spacers need to be accounted for.

Keywords: knee arthroplasty; periprosthetic joint infection; two-stage protocol; static spacer; articulated spacer; knee revision surgery

1. Introduction

Periprosthetic joint infection (PJI) is one of the main complications following primary total knee arthroplasty (TKA), with high morbidity and a significant negative impact on the outcome. Because of the increase in the number of arthroplasties, the incidence of PJI has been increasing steadily as well, and it has been reported to range from 0.5% to 1.9%, currently representing a growing social and economic issue for health systems [1,2]. Treatment of PJI represents one of the main challenges of modern orthopedics, requiring a multidisciplinary approach, as it aims for infection control, pain relief, and restoration of joint function [3].

The main treatment options for primary PJIs include debridement and implant retention (DAIR), even with the use of local adjuvants (Debridement, Antibiotic Pearls, and Retention of the Implant—DAPRI) [4], single-stage revision, one-and-half revision with long-lasting spacer, and two-stage revision. Currently, there are well-established guidelines for the management of infections after knee arthroplasty, with DAIR recommended only for early infections with an immature bacterial biofilm and exchange of the prosthesis required for late infection or in case of implant loosening [5,6]. In particular, two-stage treatment has proven to be the most cross-adaptive and the most recommended in cases of infections with highly virulent bacteria and/or bone or soft tissue problems (with possible...
The two-stage procedure consists of the removal of the infected prosthesis and cement, followed by extensive debridement of the non-viable tissue and multiple washes. A temporary spacer impregnated with antibiotic is then implanted and left in place for a variable amount of time. Postoperatively, long-term antibiotic therapy is set up. Empirical intravenous broad-spectrum antibiotic therapy is generally begun immediately after surgery. After culture results, antibiotic therapy is modified, using an oral regimen whenever possible [10].

The reimplantation is performed once the infection has been eradicated, on the basis of clinical and laboratory criteria. However, if there is any suspicion of persistent infection, a repeat debridement with exchange of the spacer should be undertaken.

The use of an antibiotic-loaded cement spacer is an established method to increase knee stability and for local antibiotic administration prior to implantation of the definitive prosthesis [11–14]. Many different types of spacers are regularly used in surgical practice. Static spacers have demonstrated excellent results over the years in terms of eradicating the infection and therefore remain a valid treatment option [8]. However, several risks associated with the use of the static spacer are described in the literature, such as reduced function between the two stages, shortening of the soft tissues, increased bone loss, and an increased risk of spacer displacement [15]. To overcome these problems, articulated spacers are increasingly used, which allow one to avoid the shortening of soft tissues, to reduce bone loss, and to guarantee the patient a better function between the two stages [16]. Several categories of mobile spacers are regularly used, including prefabricated cement-on-cement components, intraoperatively molded cement-on-cement and cement-on-polyethylene components, and autoclaved femoral component on polyethylene [17].

Currently, the scientific evidence to support the use of static or articulated spacers is still not conclusive, both for the functional outcomes and the infection eradication rates. Thus, the choice is often determined by the surgeon’s experience.

The aim of this systematic literature review is to provide a comprehensive data collection on two-stage reimplantation using different types of spacers, in terms of infection control, complications, and functional outcomes.

2. Materials and Methods

This systematic review was conducted in accordance with the 2020 PRISMA guidelines (Preferred Reporting Items of Systematic Reviews) [18].

All studies (randomized controlled trials (RCT), prospective (PCCS) and retrospective comparative studies (RCCS), prospective (PCS) and retrospective case series (RCS)) reporting the use of static or articulated cement or hybrid metal/cement/polyethylene spacers in two-stage surgery to treat PJI of a primary knee arthroplasty were included. The two-stage surgical protocol consists of the following: (1) a first surgery with total removal of the infected implant, extended surgical debridement, and placement of a spacer (usually an antibiotic-laden spacer)—this step may be repeated in the case of failure to control the infection; (2) a second surgery for further debridement and reimplantation (regardless of the type of implant used).

No restrictions were made based on the initial indication for knee replacement surgery, as the study focused on the treatment outcome of a complication, namely the PJI. Due to the wide time window of the studies included in this review, the definition of PJI has not been uniformly stated. The criteria adopted by the individual authors for the most recent studies are those which were discussed in the 2018 International Consensus Meeting on Orthopedic Infections [5]. With regard to the remaining articles, the authors of this review unanimously agreed that the criteria adopted by the authors of the individual studies included in this review were always diagnostically appropriate to identify patients with plausible PJI. Otherwise, non-conforming studies were excluded.

Studies reporting the results of PJI treatments other than two-stage protocols (including DAIR with or without partial component replacement, single-stage with partial or total explantation, one-and-half procedure with long-lasting spacer, permanent spacer,
megaprosthesis, and resection arthroplasty) were excluded. Studies reporting the results of various treatments of knee PJI were excluded. Cases in which single- or two-stage protocols were used in the treatment of a recurrence of infection were excluded. Only studies with a minimum follow-up of 12 months and a minimum of 5 patients were included. Biomechanical studies, cadaveric studies, “in vitro” studies, and animal model studies were excluded. Only studies in English were included.

Studies eligible for this systematic review were identified through an electronic systematic search of the studies published from 1 January 2000 up to 30 June 2022, published on PubMed (https://pubmed.ncbi.nlm.nih.gov/ (accessed on 30 June 2022)), Scopus (https://www.scopus.com (accessed on 30 June 2022)), and Web of Science (www.webofscience.com (accessed on 30 June 2022)) databases. Terms used for the search included “infection”, “prosthesis-related infection”, “knee joint”, “knee arthroplasty”, “knee replacement”, “peri-prosthetic infection”, “2-stage”, “two-stage”, “explant”, “re-implantation”, “static spacer”, “articulated spacer”, “mobile spacer”, “dynamic spacer”. Articles that were considered relevant by electronic search were retrieved in full text, and a cross-referencing search of their bibliographies was performed, to find further related articles. Reviews and meta-analyses were also analyzed, in order to broaden the search to studies that might have been missed through the electronic search. All duplicates were removed, and all the articles retrieved have been analyzed. After the first screening, records without eligibility criteria were excluded (Figure 1). Remnant studies were categorized by type, according to the Oxford Centre for Evidence-Based Medicine (OCEBM). To assess the quality of the articles, the revised Cochrane risk-of-bias tool for randomized trials (RoB2) (Figure 2a) and the Cochrane risk of bias in non-randomized studies of interventions (ROBINS-I) assessment tool (Figure 2b) were utilized [19,20]. Each study was assessed by two reviewers (Ma.F. and L.M.) independently and in duplicate; disagreement was resolved by the senior author (M.D.). All the included studies were analyzed, and data related to topics of interest were extracted and summarized (Tables 1 and 2).

Figure 1. PRISMA 2020 flow diagram and the selection of studies.
Table 1. Data from series reporting on static spacers.

| Article                  | Level of Evidence | Study Type | Patient N (Spacer N°) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time of PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (%) | PJI Recurrence (%) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection Related-Complications (%) |
|--------------------------|-------------------|------------|-----------------------|----------------|-------------------------|-----------------------------------------------|-------------------------|----------------------------------------|-------------------------------------------------|------------------|----------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Akhtar et al., 2019 [21] | 3                 | RCCS       | 17                    | 81.3           | 46                      | N/A                                           | N/A                     | 2                                      | 9 (N/A)                                        | N/A              | N/A            | N/A                                           | N/A                                           | N/A                                           | N/A                                           |
| Barrack et al., 2000 [22]| 3                 | PCCS       | 28                    | 68.5           | 36 (range 24-60)        | N/A                                           | N/A                     | 0                                     | 0.9-14 (N/A)                                   | 2 (arthrodesi)                     | N/A            | N/A (range 4-7)                               | N/A                                           | KSS: 115                                         | N/A                                           |
| Bru neonkreef et al., 2013 [23] | 3            | RCCS       | 9                     | 61             | 12                      | 62.4                                         | N/A                     | 0                                     | 3.6 (range 1–10)                               | 0                 | 0             | /                                              | 6                                             | 73.8                                          | N/A                                           |
| Chen et al., 2016 [24]  | 3                 | RCCS       | 8                     | 73.9 (range 63-82) | 40.8                    | N/A                                           | N/A                     | 0                                     | 5.1 (range 1.6–13.8)                          | 0                 | 2             | 17.5 (N/A)                                    | 6                                             | 74.3 (range 50-90)                              | KSS: 71.4 (range 60-81)                      |
| Chiang et al., 2011 [25] | 3                 | PCCS       | 22                    | 72 (range 67-80)  | N/A                     | N/A                                           | N/A                     | 1                                     | 3.1 (range 2–4)                               | 1                 | 2             | N/A                                           | 11.7                                          | 85 (range 70-100)                               | 0 (range artrodesi)                          |
| Choi et al., 2012 [26]  | 3                 | RCCS       | 14                    | N/A             | N/A                     | N/A                                           | N/A                     | 0                                     | 6 (N/A)                                       | 4                 | 7             | N/A                                           | 6                                             | 97 (range 75-130)                              | N/A                                           |
| Emerson et al., 2002 [27] | 3               | RCCS       | 26                    | 65.7           | 90 (range 33.6-152.4)   | N/A                                           | N/A                     | 0                                     | N/A (range 6-12)                              | 0                 | 8             | N/A                                           | 6                                             | 93.7                                          | N/A                                           |
| Faschingbauer et al., 2016 [28] | 4             | RCS        | 133                   | 70.1 ± 9.9     | N/A                     | N/A                                           | 0 (N/A)                 | 2.8                                    | 32 (range 16-10)                              | N/A              | 3             | N/A                                           | 6                                             | 98 ± 17 (range 50-120)                         | HSS: 83 (range 37-98)                         |
| Fehring et al., 2000 [29] | 3                 | RCCS       | 25                    | N/A             | 36 (range 24-72)        | N/A                                           | N/A                     | 0                                     | 3 (N/A)                                       | 6                 | N/A            | N/A                                           | KSS: 45 (range 35-80)                         | N/A                                           | N/A                                           |
| Freeman et al., 2007 [30] | 3                 | RCCS       | 28                    | 71.2           | 86.6 (range 24-196.3)   | N/A                                           | N/A                     | 0                                     | N/A                                           | 6                 | N/A            | KSS: 83 (range 37-98)                         | N/A                                           | N/A                                           |
| Gharen et al., 2016 [31] | 3                 | RCCS       | 5                     | N/A             | N/A                     | N/A                                           | N/A                     | 0                                     | N/A                                           | 3                 | N/A            | range 4-6                                     | N/A                                           | N/A                                           |
| Haleem et al., 2004 [32] | 4                 | RCS        | 96                    | 69 (range 37-89)  | 86.4 (range 30.0–156.4) | 26.2 (range 0.5-177)                          | 26.0% MSSA; 14.8% MRSA | N/A                                    | 1.4 (range 0.2-80.4)                          | 9                 | 12 (range 1.2-17.6)                          | 5.3 (range 1-24)                             | 90 (range 30-120)                              | KSS: 89 (range 35-97)                         |
| Hipfl et al., 2019 [33]  | 4                 | RCS        | 97                    | 70 (range 30-88)  | 41 (range 27-36)        | N/A                                           | 42% CoNS; 22% P. acnes | 9                                      | 2.1 (range 1.2-5.5)                           | 0                 | 15 (range 1-26)                              | 10 (range 6-24)                             | N/A                                           | N/A                                           |
| Husted et al., 2002 [34] | 4                 | RCS        | 17                    | 72.2 ± 36.8     | 68.3 (range 8-197)      | N/A                                           | 15.6% S. epidermidis; 12.5% MSSA               | 45.2% S. aureus; 41% S. epidermidis       | 0                | 7.4 (range 2.3-29.7)                         | N/A                                           | N/A                                           | range 6-8                                     |
| Husted et al., 2002 [35] | 4                 | RCS        | 32                    | 66 (range 50-78)  | 68.3 (range 8-197)      | N/A                                           | 15.6% S. epidermidis; 12.5% MSSA               | 24% CoNS; 19% S. aureus                 | 0                | N/A                                           | 2                 | 2             | 5.4                                           | 99.3 (range 70-130)                           | N/A                                           | N/A                                           |
| Ippolito et al., 2021 [36] | 4                | RCS        | 21                    | 52.4 ± 20.6     | 123.6 ± 76.8 (range 20.4-291.6) | 57.4 (range 3-246)                         | N/A                     | 0                                      | N/A                                           | 1                 | 7             | N/A                                           | 12                                             | 100 ± 17 (range 70-130)                       | N/A                                           |
Table 1. Cont.

| Article                              | Level of Evidence | Study Type | Patient N (Spacer N°) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time of PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | Mean Time of PJI Recurrence (N°) | PJI Recurrence (N°) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N°) |
|--------------------------------------|-------------------|------------|-----------------------|-----------------|-------------------------|-----------------------------------------------|------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------------------------------|
| Johnson et al., 2012 [38]           | 3                 | RCCS       | 81                    | 61 (range 58–64) | 66 (range 12–121)       | N/A                                           | N/A                    | N/A                                   | 3.5 (range 2.7–4.3)                           | N/A                                   | 14               | N/A                                         | 95 (range 30–130)                                      | KSS: 84 (range 48–100)                                 | 0                                                  |
| Kong et al., 2021 [39]              | 3                 | RCCS       | 22                    | 67.2 ± 10.1      | 4 (range 30–61)         | N/A                                           | N/A                    | 1                                    | 3 (range 1.8–5.5)                            | 0                                      | 1    | N/A                                         | 80 (range 70–110)                                     | KSS: 60 ± 6.3                                     | 0                                                  |
| Lisachotin et al., 2016 [40]        | 4                 | RCS        | 109                   | 67 (range 42–49)  | 44.4 (range 24.0–117.6) | N/A                                           | 51% Staphylococcus spp.; 19% Streptococcus sp. | 0                     | N/A                                   | 11 (range 5–20)                                | 100 (range 63–139)                                 | KSS: 86 (range 65–98)                                | N/A                                                  |
| Lo Presti et al., 2021 [41]         | 4                 | RCS        | 12                    | 64 (range 39–85)  | 34.3 (range 10–62)      | N/A                                           | 25% MRSA; 16% E. faecalis | 4                     | N/A                                   | N/A (range 6–8)                               | N/A                                   | N/A                                         | 0                                                  |
| Ma et al., 2020 [42]                | 3                 | RCCS       | 66                    | 70.3 ± 11.0 (range 19–86) | 75.3 ± 30.6 (range 24–133) | N/A                                           | N/A                    | 6                                    | 4                                      | 2                                      | 0 / SHC: 0.7 STC: 14.7                      | N/A                                         | N/A                                                  |
| Nathus et al., 2020 [43]            | 1                 | RCT        | 24                    | 64.9 ± 8.4       | 42 ± 14.4               | N/A                                           | N/A                    | 2                                    | 2.4 ± 0.7 (range 2.1–2.8)                                                      | 103 ± 12.7 (range 97.6–108.3)                       | KSS: 69.5 ± 14.1                                      | 13                                                  |
| Park et al., 2010 [44]              | 3                 | RCCS       | 20                    | 66.5 (range 48–84) | 36 (range 24–62)        | N/A                                           | 30% MRSA; 20% MSSA | N/A                                   | N/A                                    | 3                                      | N/A                                         | 92 (range 65–140)                                     | HSS: 80 (range 74–97)                                | N/A                                                  |
| Petos et al., 2019 [45]             | 4                 | RCS        | 240                   | N/A              | N/A                    | N/A                                           | N/A                    | N/A                                   | N/A                                    | N/A                                   | N/A                                         | N/A                                         | N/A                                                  |
| Poborchenskaya et al., 2019 [46]    | 3                 | RCCS       | 25                    | N/A              | 12                     | N/A                                           | N/A                    | N/A                                   | 0                                      | N/A                                   | 0 / N/A                                      | N/A                                         | N/A                                                  |
| Rossi et al., 2021 [47]             | 3                 | RCCS       | 13                    | N/A              | 18                     | N/A                                           | N/A                    | 0                                    | 0                                      | 0 / N/A                                | N/A (range 6–8)                                    | N/A                                         | N/A                                                  |
| Schröder et al., 2022 [48]          | 3                 | RCS        | 47                    | 63 (range 9–30)   | N/A                    | N/A                                           | N/A                    | N/A                                   | 2                                      | 10                                    | N/A                                         | N/A                                         | 90.5                                                  |
| Silvestre et al., 2013 [49]         | 4                 | RCS        | 43 (45)               | 72 (63–81)       | 86 (range 60–132)       | N/A                                           | 17.8% Staphylococcus spp.; 13.8% MSSA | N/A                                   | 4                                      | 2                                      | 2 / SHC: 0.7 STC: 14.7                      | N/A                                         | 92 (range 50–115)                                    | 7                                                  |
| Skewara et al., 2016 [50]           | 3                 | RCCS       | 21                    | N/A              | 8.5                    | N/A                                           | N/A                    | N/A                                   | N/A                                    | 2                                      | N/A                                         | N/A                                         | 79 ± 26                                                | 1                                                  |
| Springer et al., 2014 [51]          | 4                 | RCS        | 34                    | 66.5 (range 48–64) | N/A                    | N/A                                           | 61.7% CoNS; 17.6% S. aureus | N/A                                   | 1                                      | 3                                      | N/A                                         | N/A                                         | 6                                                      | N/A                                                  |
| Vasarhelyi et al., 2022 [52]        | 3                 | RCCS       | 76                    | 69.4 ± 10.0      | 228 ± 75.6              | N/A                                           | 51.4 (range 3–120) | N/A                                   | 4                                      | 3                                      | N/A                                         | N/A                                         | 6                                           | 82.1 ± 25.4                                      | 9                                                  |
| Vugul et al., 2021 [53]             | 4                 | RCS        | 77                    | 64.9 (range 31.3–82.4) | 24.5 (range 6–107) | 23.6 (range 6–336) | N/A                                           | 17                                   | 3.2 (range 1.8–7.3)                    | 2                                      | 14                                    | 19.5 (range 0–63.9)                                 | N/A                                         | N/A (range 6–8)                                    | N/A                                                  |
| Zamora et al., 2020 [54]            | 3                 | RCCS       | 14                    | N/A              | N/A                    | N/A                                           | N/A                    | 1                                    | N/A                                    | 2                                      | 2 / SHC: 0.7 STC: 14.7                      | N/A                                         | N/A                                                  |

Abbreviations: RCT, randomized controlled trial; PCCS, prospective comparative cohort study; RCCS, retrospective comparative cohort study; PCS, prospective case series; RCS, retrospective case series; CoNS, coagulase-negative staphylococci; MSSA/MRSA, methicillin-sensitive/resistant Staphylococcus aureus; SHC, short-course antibiotic therapy; STD, standard-course antibiotic therapy; PJI, periprosthetic joint infection; FU, follow-up; KSS, Knee Society Score; HSS, Hospital for Special Surgery Knee-Rating Scale; N/A: data not available.
Table 2. Data from series reporting on articulated spacers.

| Article                      | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n) | PJI Recurrence (n) | Mean Time to Recurrence (Months) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N) |
|------------------------------|-------------------|------------|----------------|---------------------|------------------|------------------------|---------------------------------|---------------------------------|-----------------------------|----------------------------------|---------------------|---------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------------|---------------------------------|
| Ahmad et al., 2013 [55]      | 3                 | PCCS       | C/C            | 75                  | 67.8 (range 57–85) | 51.6 (range 24–84) | N/A                         | 27.9%, S. aureus; 25.6% CoNS; 11.6%     | 0                            | N/A                           | 1                                 | 7                                      | 42                                | N/A (range 0–7.5) | 115 (range 90–125) | KSS: 89.5 (range 74–95) | N/A                                      |
| Akhtar et al., 2019 [21]     | 3                 | RCCS       | C/C Pedestal C/C | 13                  | 69                | 32.9                  | N/A                         | N/A                                           | 2                            | N/A                           | 1                                 | 7                                      | N/A                              | N/A                                   | N/A                              | N/A                                      |
| Rabi et al., 2018 [56]       | 4                 | PCS        | C/C            | 24                  | 71 (range 58–84)  | 72 (range 24–120)    | N/A                         | 58.3% S. aureus; 42.9% S. epidermidis | 0                            | 1.4                            | 0                                 | 0                                      | /                                 | 6                                  | 100                              | N/A                                      |
| Bodich et al., 2008 [57]     | 4                 | RCS        | C/C            | 60                  | 67.8 (range 46–85) | 35.6 (range 1–135)   | 53.5 (range 2–239)          | S. aureus; S. epidermidis          | 0                            | 1.4                            | 0                                 | 0                                      | /                                 | 4.2                                | (range 3–7) | 110 (range 105–125) | KSS: 86.4 (range 74–97) | N/A                                      |
| Brunneke et al., 2013 [53]   | 3                 | RCCS       | M/P            | 26                  | 58                | 12                    | 56.4                         | N/A                                           | 0                            | 4.4                            | 0                                 | 0                                      | N/A                              | 6                                  | 96.4                             | N/A                                      |
| Buyuk et al., 2017 [58]      | 4                 | PCS        | C/C            | 25                  | 70 ± 9.7 (range 52–86) | 39 ± 12.5 (range 22–73) | N/A                         | 36% MRSE; 12% MSSA | 2                            | 3.8 ± 1.4 (range 2–6)          | 0                                 | 1                                 | 9.3 ± 3.4                         | N/A                                   | 4.2 (range 3–7) | 110 (range 105–125) | KSS: 77 (range 52–96) | N/A                                      |
| Carulli et al., 2013 [59]    | 4                 | PCS        | M/P            | 9                   | 66.5 (range 59–71) | 55.2 (range 48–84)   | 15.5 (range 5–32)           | 80% S. aureus; 10% S. epidermidis | 0                            | 1.9                            | 0                                 | 0                                      | /                                 | 4.2                                | (range 3–7) | 110 (range 105–125) | KSS: 86.4 (range 74–97) | N/A                                      |
| Castellino et al., 2014 [60] | 4                 | PCS        | C/C            | 50                  | 68 (range 54–80)  | 84 (range 24–156)     | N/A                         | 46% CNNS; 11% MSSA | 0                            | 3.7                             | 0                                 | 4                                 | 12.8                              | 6                                  | 94                               | KSS: 75.38                         |
| Chen et al., 2016 [24]       | 3                 | RCCS       | M/P (autoclaved) | 10                 | 68.9 (range 20–88) | 32 (range 24–46)       | N/A                         | N/A                                           | 4.4                            | 4.4                            | 0                                 | 2                                      | 13 (range 5–7) | 6                                  | 94.5 (range 70–125) | KSS: 74.7 (range 62–88) | 3                                      |
| Chiang et al., 2011 [25]     | 3                 | PCCS       | C/C            | 23                  | 71 (range 65–78)  | N/A                    | N/A                         | N/A                                           | 3.4                            | 3.4                            | 0                                 | 1                                      | 11.2                              | 113 (range 95–125) | HSS: 90 (range 86–94) | 0                                      |
| DelBo et al., 2020 [15]      | 3                 | RCCS       | C/C            | 77                  | 63 (range 42–83)  | N/A                    | N/A                         | N/A                                           | 4.4                            | 4.4                            | 2                                 | 14                                     | N/A                               | 6                                  | N/A                              | N/A                                      |
| Durbakula et al., 2004 [61]  | 4                 | RCS        | C/C            | 24                  | 72 (range 44–94)  | 33 (range 28–51)      | N/A                         | 37.5% S. epidermidis; 25% S. aureus | 0                            | 2.8                            | 0                                 | 0                                      | /                                 | 6                                  | 104 (range 89–122) | HSS: 82 (range 63–96) | 2                                      |
| Evans 2004 [62]              | 4                 | RCS        | C/C            | 31                  | 64                | >24                   | N/A                         | 29% MBSSA; 25% MSSA | 0                            | 2.4                             | 2                                 | 3                                 | 21.3                              | 6                                  | 111 (range 0–130) | N/A                              | 1                                      |
| Fehring et al., 2013 [27]    | 3                 | RCCS       | C/C            | 30                  | N/A               | 27 (range 24–36)      | N/A                         | N/A                                           | 1.1                            | N/A                            | 1                                 | 1                                      | N/A                               | 6                                  | 105 (range 90–126) | HSS: 84 ± 13 (range 45–95) | 2                                      |
| Article | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n) | PJI Recurrence (n) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N) |
|---------|------------------|------------|----------------|---------------------|----------------|------------------------|------------------------------------------|-------------------------|-----------------------------|--------------------------------------------|----------------|----------------|----------------------------------|---------------------|------------------------------------------|------------------------------------------|
| Fei et al., 2022 [63] | 3 | RCCS | C/C | 23 | 67.6 ± 9.4 (range 52–81) | 46.6 ± 22.4 (range 14.4–91.3) | N/A | 30.4% S. epidermidis; 17.4% S. aureus | 0 | 3.6 ± 2 (range 2.2–10.9) | 4 | 0 | / | 57.4 ± 9.2 (range 60–90) | KS9: 84.1 ± 5.6 (range 73–95) | 0 |
| Freeman et al., 2007 [30] | 3 | RCCS | C/C | 48 | 64.9 | 62.2 (range 25.7–119.6) | N/A | N/A | 0 | 18 (range 6–42) | 7 | 0 | / | N/A (range 10–12) | 75.6 | N/A |
| Garg et al., 2011 [64] | 4 | RCS | C/C | 36 | 62 (range 30–76) | 62.4 | 10 (range 7–16) | N/A | N/A | 0 | 18 (range 6–42) | 7 | 0 | / | N/A (range 10–12) | 75.6 | N/A |
| Ghanem et al., 2016 [31] | 3 | RCCS | C/C | 30 | N/A | N/A | N/A | N/A | N/A | N/A | 2 | 8 | N/A | N/A | N/A | N/A |
| Ghanem et al., 2018 [65] | 4 | RCS | C/C | 16 | 72.0 ± 8.3 | 22.5 ± 16.6 | N/A | 37.5% S. aureus; 31.2% S. epidermidis | 0 | 6.2 ± 5.2 | 0 | 4 | N/A | N/A (range 4–6) | 103.3 ± 17.1 | N/A |
| Gooding et al., 2011 [66] | 4 | RCS | M/P | 115 | 68 (range 55–86) | 108 (range 60–144) | N/A | 32.2% S. epidermidis; 21.7% S. aureus | 2 | 3.9 (range 1.2–28.3) | 2 | 14 | N/A | > 5 | 93.2 (range 30–140) | N/A |
| Ha et al., 2010 [67] | 4 | RCS | C/C | 12 | 65.2 (range 54–73) | N/A | N/A | 26% MSSA; 16.7% MSBA | 2 | 2.1 (range 0.9–3.7) | 0 | 0 | / | N/A (range 75–140) | 102 | N/A |
| Haddad et al., 2009 [68] | 4 | RCS | M/P | 45 | 69 (range 52–83) | 48 (range 20–112) | N/A | 40% S. epidermidis; 20% S. aureus | N/A | 3.6 (range 0.6–22.3) | 1 | 4 | N/A | N/A | 94.5 (range 20–135) | HSS: 71.5 (range 52–96) |
| Hammerich et al., 2021 [69] | 4 | RCS | Reverse C/C (convex tibia + concave femur) | 110 | 67.2 (range 43–89) | N/A | 41.0 ± 3.4 (range 1–240) | N/A | 3 | 1.8 | 0 | 0 | / | N/A | N/A | N/A |
| Hart et al., 2006 [70] | 4 | RCS | C/C | 48 | 68.2 (range 37–81.3) | 48.5 (range 26–85) | 39.6 (range 5–72) | 62.5% CoNS; 10.4% S. aureus | 0 | 4.3 (range 1.4–15) | 2 | 6 | N/A | 2 | 92 (range 30–120) | N/A |
| Hochino et al., 2021 [71] | 4 | PCS | C/C | 7 | 77 | 54 ± 28 (range 11–89) | 28 ± 16 (range 10–53) | N/A | 0 | 6 ± 3 (range 3–12) | 0 | 0 | / | 3 | 99 ± 22 | KS9: 84 ± 10 |
| Hsu et al., 2007 [72] | 3 | RCCS | C/C | 21 | N/A | N/A | N/A | N/A | N/A | 0 | 3.2 (range 1.4–5.5) | 0 | 2 | 17.3 | 8.4 (range 6–12) | 95 (range 80–120) | KS9: 88.9 | N/A |
| Incavo et al., 2009 [73] | 4 | RCS | C/C | 11 | 61.1 (range 32–83) | N/A | 37 (range 4–108) | 45.3% S. aureus | N/A | N/A | 0 | 0 | / | N/A | N/A | N/A | N/A |

**Table 2. Cont.**
| Article | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N°) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n°) | PJI Recurrence (n°) | Mean Time to Recurrence (Months) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-up (Degrees) | Functional Outcomes at Last Follow-up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (n°) |
|---------|------------------|------------|----------------|----------------------|-----------------|-----------------------|---------------------------------------------|-------------------------------|------------------------------------------|-------------------------------------------------|-----------------|----------------|-------------------------------|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Jia et al., 2012 [73] | 4 | RCS | C/C | 21 | 64.4 | 32.2 (range 17–54) | 12.9 (range 8–26) | 42.9% S. epidermidis; 19% S. aureus | 1 | 2.7 (range 1.4–7.4) | 0 0 / 6 | N/A | 4.9 (range 2.8–6) | 94.3 | KSS: 82.1 | 16 |
| Johnson et al., 2012 [38] | 3 | RCCS | C/C or M/C | 34 | 62 (range 59–65) | 27 (range 12–72) | N/A | N/A | N/A | N/A | 3.1 (range 2.4–3.7) | N/A | 6 | N/A | N/A | 99 (range 60–120) | KSS: 83 (range 48–99) | 4 |
| Jung et al., 2022 [74] | 3 | RCCS | C/C | 12 | 74.5 (range 63–85) | N/A | N/A | 25% MSSA; 16.7% E. coli | 0 | 1.9 (range 1.4–2.9) | 0 0 / N/A | N/A | 3.1 (range 2.4–3.7) | N/A | N/A | N/A | 0 |
| Kalore et al., 2012 [75] | 3 | RCCS | M/P (autoclaved) | 15 | 67.3 | 73 (range 37–105) | 38.5 | N/A | N/A | N/A | 1 | 2.7 | 1 | 1 | N/A | > 6 | 98.3 | N/A | 0 |
| Kong et al., 2021 [39] | 3 | RCCS | C/C | 20 | 65.5 ± 11.4 | 18 (range 8–28) | N/A | N/A | 1 | 2.9 (range 2.1–5.1) | 0 1 | N/A | N/A | 94 (range 80–115) | KSS: 75 ± 11.5 | 4 |
| Kohl et al., 2011 [76] | 4 | PCS | C/C | 16 | 73.1 (range 54–69) | > 24 | N/A | N/A | 43.8% CoNS; 12.5% S. aureus | 0 | 3.5 (range 3–5) | 0 0 / N/A | 114 (range 90–125) | N/A | 14 (range 78–95) | N/A |
| Lin et al., 2021 [77] | 3 | RCCS | C/C | CR: 66 | 64.4 (range 57–84) | 58.3 (range 31–82) | N/A | 31.9% Staphylococcus spp.; 21.3% Streptococcus spp | 5 | 3.5 (range 2.5–6.4) | 4 | 8 | N/A | > 4 | N/A | N/A | 37 |
| Lu et al., 2018 [78] | 4 | RCS | C/P | 11 | 69.9 (range 59–69) | 24 (range 12–48) | N/A | N/A | 63.6% S. aureus; 27% S. epidermidis | 0 | N/A | 0 0 / 6 | N/A | 93.2 (range 80–105) | KSS: 84.9 (range 80–92) | 0 |
| MacAvoy et al., 2005 [79] | 4 | RCS | C/C | 13 | 58 (range 36–71) | 28 (range 15–44) | N/A | N/A | 38.9% S. epidermidis; 30.8% S. aureus | 0 | N/A | 2 4 / 6 | 98 (range 45–133) | N/A | 5 |
| Macheras et al., 2011 [80] | 4 | RCS | C/C | 34 | 64 (range 45–73) | 145.2 (range 120–168) | N/A | N/A | 41.1% S. aureus; 20.6% S. epidermidis | 0 | N/A | 1 3 | N/A | 105 (range 95–120) | KSS: 76 ± 18 (range 38–94) | 1 |
| Article                  | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N°) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n°) | PJI Recurrence (n°) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N°) |
|-------------------------|-------------------|------------|----------------|----------------------|-----------------|------------------------|-----------------------------------------------|------------------------|--------------------------------------|---------------------------------------------------------------|------------------------|----------------|-----------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|----------------------------------------------------------|
| Marothi et al., 2016 [81] | 4 RCS C/C         | 28         | 70 (range 56–79) | N/A                  | 4               | N/A                    | 0                              | N/A (range 1.4–1.9)                         | 0                      | 0                      | /                                           | 6 N/A  N/A                                               | 2                                                                         |                                                                         |
| Mutimer et al., 2009 [82]| 4 RCS C/C         | 12         | 71              | 10                   | N/A             | N/A                    | 3.5                           | (range 2.4–9.0)                           | 0                      | 0                      | /                                           | 6 N/A  N/A                                               | 0                                                                         |                                                                         |
| Nahhas et al., 2020 [43]| 4 RCT C/C         | 25         | 65.7 ± 8.9      | 42 ± 16.8            | N/A             | N/A                    | 1                              | 2.5 ± 1.2 (range 2.0–3.0)                  | 1                      | 1                      | N/A                                          | 6 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Nodaro et al., 2017 [16]| 3 RCCS Preformed C/C | 58         | 65.3 ± 8.6      | 74.9 ± 35.1          | N/A             | N/A                    | 2.5 (range 1.8–3.3)                | N/A                                  | 10                                                                 | 5 N/A  N/A  N/A  N/A | N/A  N/A | N/A  N/A  N/A  N/A | N/A  N/A  N/A  N/A | 6 | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Odegard et al., 2010 [83]| 3 RCCS Molded C/C | 43         | 66 ± 11.0       | 43.7 ± 16.7          | N/A             | N/A                    | 2.3 (range 1.8–3.2)               | N/A                                  | 5                                                                 | 4 N/A  N/A | N/A  N/A | N/A  N/A  N/A | N/A  N/A  N/A | 6 | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Orsina et al., 2017 [44]| 4 RCS C/C         | 112        | 56.2 ± 16.9     | 32.9 ± 12            | 36.8 ± 63.6     | N/A                    | 25.9%                          | S. aureus; 22.3% S. epidermidis            | 7                      | 2.1 ± 0.4 | 15 | 3 N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Park et al., 2010 [44]  | 3 RCCS C/C         | 16         | 60.2 (range 47–72) | 29 (range 25–45) | N/A             | 25% MSSA; 25% C. Albican   | N/A                             | N/A                                  | 10                                                                 | 6 N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Pascale et al., 2007 [85]| 4 RCS C/C         | 14         | 68 (range 60–76) | N/A                  | 27.6 (range 12–36) | 71.4% S. epidermidis      | 0                              | 4.2                                  | 12                                                                 | 6 N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Pitto et al., 2005 [86] | 4 RCS C/C         | 21         | 67 (range 58–69) | 24 (range 12–43)    | N/A             | 57.1% Streptococcus spp.; 14.2% S. aureus | 1                              | 3                                  | 2 N/A                                          | 6 94 | 94 | 94 | 94 | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Preobrazhensky et al., 2019 [46]| 3 RCCS M/P (autoclaved) | 67 | N/A             | 12                   | N/A             | N/A                    | 1                              | N/A                                  | 0                                                                 | 1 N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Radovic et al., 2016 [87]| 4 RCS C/C         | 18         | 66.6            | N/A                  | N/A             | Multi-bacterial          | 3                              | N/A                                  | 2                                                                 | N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Roof et al., 2021 [88]  | 3 RCCS C/C or M/P (new) | 72 | 63.4 ± 11.7 | 24                   | N/A             | N/A                    | 6                              | N/A                                  | 8                                                                 | N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
| Rossi et al., 2021 [47] | 3 RCCS C/C or M/P (autoclaved) | 27 | N/A             | 18                   | N/A             | N/A                    | 1                              | N/A                                  | 0                                                                 | 1 N/A  N/A | N/A  N/A | N/A  N/A | N/A  N/A | 114.0 ± 100.5 (range 109.7–118.3) | KSS: 79.4 (range 72.4–86.3) | 8                                                                         |
## Table 2. Cont.

| Article | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n) | PJI Recurrence (n) | Mean Time to Recurrence (Months) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N) |
|---------|------------------|------------|----------------|---------------------|-----------------|-------------------------|-----------------------------------------------|------------------------|----------------------------------------|---------------------------------------------|------------------------|------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Sakellarious et al., 2015 [89] | 4 | PCS | C/C | 46 | 65.3 (range 32–84) | 36 (range 8–60) | 33.6 (range 4–84) | 39.1% S. aureus; 26.1% Staphylococcus spp. | 0 | N/A | 0 | 6 | N/A | N/A | N/A | N/A | 3 |
| Schoeder et al., 2022 [86] | 3 | RCCS | M/P (new) | 30 | 65.6 (range 11.4) | N/A | N/A | N/A | N/A | 2 | 6 | N/A | N/A | 99.3 | N/A | 5 |
| | | | C/C | 19 | 64.6 (range 11.7) | N/A | N/A | N/A | N/A | 2 | 6 | N/A | N/A | 77.2 | N/A | 5 |
| Geo et al., 2020 [80] | 4 | RCS | C/C | 14 | 70.2 ± 6.3 | 44.9 ± 6.5 | N/A | Streptococcus spp.; 21.4% S. aureus | 0 | N/A | 0 | 0 | / | N/A | 92.9 | N/A | 0 |
| Shikh et al., 2014 [95] | 4 | RCS | C/C | 13 | 65 | 48 | N/A (range 0.5–18) | 15.4% MSSA, 15.4% C. Albicans | 1 | 5.6 (range 2–29) | 0 | 0 | / | > 2 | 115 (range 75–130) | KSS: 83 | 0 |
| Shem et al., 2010 [92] | 4 | RCS | C/C | 17 | 67 (range 52–76) | 31 (range 18–47) | N/A | Streptococcus spp.; 23.9% S. aureus | N/A | 7.8 | 7 | 1 | N/A | > 6 | 95.4 (range 90–105) | HSS: 83.6 | 10 |
| Siebel et al., 2005 [81] | 4 | RCS | C/C | 10 | 66.1 | 18.1 | N/A | 20% S. epidermidis; 10% S. aureus | 0 | 1.9 (range 1.4–2.8) | 0 | 0 | / | N/A | 86.5 | HSS 63.8 | 0 |
| Skogera et al., 2016 [85] | 3 | RCCS | C/C | 16 | N/A | 8.5 | N/A | N/A | N/A | N/A | N/A | 1 | N/A | N/A | 102 ± 8.4 | N/A | 0 |
| Strudens et al., 2013 [84] | 4 | RCS | C/C | 154 (135) | 66 ± 11 | N/A | N/A | N/A | N/A | 1.8 ± 0.79 | N/A | N/A | N/A | N/A | N/A | N/A | 82 |
| Su et al., 2009 [95] | 4 | RCS | C/C | 15 | 72 (range 65–79) | 47.5 (range 37–61) | N/A | 60% MSSA; 10% CoNS | 0 | 3 | 2 | 1 | N/A | N/A | 110 (range 95–120) | HSS: 90.5 (range 52–92) | 1 |
| Thabo et al., 2007 [96] | 4 | RCS | C/C | 20 | 72.3 (range 48–83) | 73.2 | N/A | N/A | 0 | 0.9 | 0 | 0 | / | N/A | 106 | N/A | 0 |
| Tian et al., 2018 [97] | 4 | RCS | C/C | 25 | 64.9 (range 56–83) | 64.2 (range 52–89) | N/A | 20% MRSE; 16% MSSE | 0 | 2.6 (range 1.4–7.3) | 0 | 0 | / | N/A | 94 (range 90–98) | KSS: 83 (range 80–88) | 8 |
| Tigrani et al., 2013 [89] | 4 | PCS | C/C | 37 (38) | 68 (range 36–86) | 65 (range 24–139) | N/A | 31.6% MSSE; 15.8% MRSE | 5 | 2.4 (range 1.6–6.9) | 2 | 9 | N/A | 6 | 101 (range 80–115) | N/A | 1 |
| Tsai et al., 2019 [99] | 4 | RCS | C/C | 32 | 73.3 (range 56–93) | 36.9 (range 30.1–43) | N/A | 21.9%, MSSA; 15.6% Enterococcus spp. | 3 | 8.8 (range 4–12.5) | 1 | 4 | N/A | > 4 | 102 (range 80–122) | HSS ± 84.2 (range 78–90) | 2 |
| Article | Level of Evidence | Study Type | Spacer Details | Patient N (Spacer N°) | Mean Age (Year) | Mean Follow-Up (Months) | Mean Time to PJI Onset after Implant (Months) | Most Frequent Pathogens | Spacer Exchange: Repeated First Stage | Mean Time between First Stage and Second Stage (Months) | No Reimplantation (n°) | PJI Recurrence (n°) | Mean Time to Recurrence (Months) | Mean Duration of Antibiotic Therapy (Weeks) | Active Knee Flexion at Last Follow-Up (Degrees) | Functional Outcomes at Last Follow-Up: Score Type and Values | Peri-Operative Non-Infection-Related Complications (N°) |
|---------|------------------|------------|----------------|-----------------------|----------------|------------------------|-----------------------------------------------|--------------------------|-------------------------------|-----------------------------------------------|------------------------|----------------|---------------------------------|-------------------------------------|---------------------------------------------|------------------------------------------------|------------------------------------------|
| Van Thiel et al., 2011 [100] | 4 | RCS | C/C | 60 | 66 (range 42–91) | 35 (range 24–51) | N/A | 22% MRSA, 20% MSSA | 1 | 2.7 | 1 | 7 | 16.3 (range 2–30) | N/A | 101.3 ± 18 | KSS: 78.8 ± 17.8 | 1 |
| Vasarhelyi et al., 2022 [52] | 5 | RCCS | C/C | 104 | 66.6 ± 116 | 120 ± 49.2 | 43.8 (range 3–168) | N/A | 7 | 3 | N/A | 17 | N/A | 6 | 116 ± 13.5 | KSS: 86.5 ± 13.6 | 4 |
| Vasso et al., 2016 [101] | 4 | RCS | C/C | 46 | 69 (range 58–84) | 144 (range 72–192) | N/A | 52% MSSA, 28.3% CoNS | 2 | 2.5 (range 2.3–3.1) | N/A | 0 | / | 8 | 115 (range 105–120) | N/A | 0 |
| Vecchini et al., 2017 [102] | 4 | PCS | C/C | 19 (20) | 65.4 (range 50–82) | 74.1 (range 10–112) | N/A | 60% MSSA, 20% MRSA | 0 | 9.1 (range 3–27) | 1 | 0 | / | 3.6 (range 2–5) | N/A | N/A | 4 |
| Villanueva-Martinez et al., 2009 [103] | 4 | RCS | C/C | 30 | 71 (range 64–82) | 36 (range 24–60) | 18 (range 1–144) | 40% CoNS, 30% MSSA | 1 | 3.5 | 1 | N/A | N/A | N/A | 107 (range 90–120) | N/A | 6 |
| Wan et al., 2012 [104] | 4 | RCS | C/C | 33 | 70 ± 11 | 44 (range 24–62) | 41 (range 1–192) | 24.2% MSSA, 24.2% CoNS | 8 | 3.2 (range 1.84–7.31) | 2 | 3 | N/A | 6 | N/A | N/A | N/A |
| Yi et al., 2015 [105] | 4 | RCS | M/P | 17 | 63.7 (range 43–74) | 43.6 (range 24–96) | N/A | 23.5% S. epidermidis; 11.8% MSSA | 1 | 3.9 (range 2.3–6.2) | 1 | 1 | N/A | 4 | 105.9 (range 90–125) | HSS: 83.9 (range 77–95) | N/A |
| Zamora et al., 2020 [54] | 3 | RCCS | M/P (new) | 3 | N/A | N/A | N/A | N/A | 1 | N/A | N/A | 0 | / | N/A | N/A | N/A | N/A | N/A |

Abbreviations: RCT, randomized controlled trial; PCCS, prospective comparative cohort study; RCCS, retrospective comparative cohort study; PCS, prospective case series; RCS, retrospective case series; C/C, cement on cement; C/P, cement on polyethylene; M/P, metal on polyethylene; M/C, metal on cement; CoNS, coagulase-negative staphylococci; MSSA/MRSA, methicillin-sensitive/resistant Staphylococcus aureus; MSSE/MRSE, methicillin-sensitive/resistant Streptococcus epidermidis; PJI, periprosthetic joint infection; CR, cruciate-retaining total knee arthroplasty; PS, posterior-stabilized total knee arthroplasty; FU, follow-up; KSS, Knee Society Score; HSS, Hospital for Special Surgery Knee-Rating Scale; N/A: data not available.
Figure 2. Cont.
Mean duration of antibiotic therapy (weeks) 7.2 ± 1.9 870 6.1 ± 1 1170 0.007
Mean duration of antibiotic therapy (months) 3.1 ± 1.1 854 3.6 ± 2.3 2071 0.480
Mean time between first and second stage
Mean time to PJI (months) 34.8 ± 14.3 296 36.8 ± 11.9 737 0.735

Most frequent bacterial population

Figure 2. Quality assessment of the included studies in meta-analysis according to RoB2 [43] (a) and ROBINS-I [21,23,25,29–31,34,38,39,44,46–48,50,52,54,106] (b) tools: “traffic light” plots of the domain-level judgments for each individual result (a,b); weighted bar plots of the distribution of risk-of-bias judgments within each bias domain (c).

In detail, data extracted included study type, mean age, mean follow-up, number and details of spacers, mean time to infection onset, bacterial populations, number of spacers used, and repeated first stages, mean time between first stage and second stage, mean duration of antibiotic therapy, number of PJI recurrences, number of cases in which no reimplantation was performed, mean active knee flexion at last follow-up, functional outcome at last follow-up, and peri-operative non-infection-related local complications. Functional outcomes were reported according to the most reported scoring systems used in the studies analyzed in this review: Knee Society Score (KSS) and Hospital for Special Surgery Knee-Rating Scale (HSS). Local peri-operative complications not related to infection were reported, including extensor lag, spacer subluxation/fracture, extensor mechanism rupture, nerve palsy, periprosthetic fracture, dislocation, instability, arthrofibrosis, hematoma, and delayed wound healing. Success of the treatment was defined as the achievement of infection control at last follow-up (the absence of clinical and/or radiological and/or laboratory signs of infection, as mentioned in the individual papers). Failure of the treatment was defined as the persistence of infection, re-infection, or no reimplantation; the repetition of the first stage of the two-stage protocol due to persistence of infection was not considered a failure when it eventually resulted in successful control of the infection at last follow-up after the end of the treatment.

Studies with reported quantitative data were used for statistical analysis (Tables 3 and 4). Weighted means and standard deviations were calculated to summarize the values reported in the individual studies and to compare them. Chi-square statistics (Pearson Chi-square, Yates Chi-Square, Fisher exact test, Fisher–Freeman–Halton test) were used to assess associations and homogeneity among categorical variables. For quantitative variables, the Shapiro–Wilk test was used to verify normal distribution. The Levene test was used to assess the equality of variances. As a parametric test, the two-tailed unpaired Student T-test was used in case of equality of the variances; otherwise, the Welch T-test was used. The Mann–Whitney U-test was used as a non-parametric test in case of non-normal distribution of the variables. Spearman’s rho was used to identify monotonic correlations between variables. Only comparative studies were included in the meta-analysis (Figures 3 and 4). Quantification of the extent of statistical heterogeneity across studies included in the meta-analysis employed the inconsistency statistic ($I^2 > 75\%$ was considered as high heterogeneity). Potential sources of heterogeneity by study level and clinically relevant characteristics were explored using stratified analysis and meta-regression. Publication bias was assessed using Egger’s regression symmetry test. $p$-value < 0.05 was considered to be significant. All statistical analyses were performed with IBM SPSS v26.0 for MacOS (SPSS Inc., Chicago, Illinois) and ProMeta 3 (Internovi, Cesena, Italy) software.
Table 3. Summarized data from the included studies of this review.

| Static | Spacers with Data Available (n) | Articulated | Spacers with Data Available (n) | p-Value |
|--------|---------------------------------|-------------|---------------------------------|---------|
| Study series (n) | 34 | 71 | | |
| • RCT | 1 | | 1 | |
| • PCCS | 2 | | 2 | 0.111 |
| • RCCS | 19 | | 23 | |
| • PCS | 0 | | 9 | |
| • RCS | 12 | | 36 | |
| Spacers (n) | 1511 | | 2739 | |
| Mean age (years) | 67 ± 5.6 | 1147 | 66.4 ± 3.5 | 2545 | 0.532 |
| Mean follow-up (months) | 68 ± 52.3 | 1002 | 53.5 ± 32.9 | 2163 | 0.117 |
| Most frequent bacterial population | | | |
| S. aureus | CoNS | 347 | S. aureus | S. epidermidis | CoNS | 1303 | |
| Mean time to PJI (months) | 34.8 ± 14.3 | 296 | 36.8 ± 11.9 | 737 | 0.735 |
| Mean time between first and second stage (months) | 3.1 ± 1.1 | 854 | 3.6 ± 2.3 | 2071 | 0.480 |
| Mean duration of antibiotic therapy (weeks) | 7.2 ± 1.9 | 870 | 6.1 ± 1 | 1170 | 0.007 |
| Repeated first stage/spacer exchange (n) | 47 (5.4%) | 922 | 89 (4%) | 2237 | 0.159 |
| No reimplantation (n) | 67 (7.1%) | 947 | 94 (4.3%) | 2198 | 0.001 * |
| PJI recurrence (n) | 157 (12.4%) | 1271 | 230 (9%) | 737 | 0.001 * |
| Mean time to PJI recurrence (months) | 13.7 ± 3.9 | 285 | 23.2 ± 12.1 | 737 | 0.125 |
| Mean active knee flexion at last FU | 91.6 ± 7 | 763 | 100.3 ± 9.9 | 1549 | <0.001 * |
| Mean KSS score at last FU | 81.1 ± 13.1 | 569 | 81.9 ± 5.5 | 732 | 0.792 |
| Mean HSS score at last FU | 81.8 ± 0.7 | 67 | 81.7 ± 7 | 229 | 0.981 |
| Peri-operative non-infection-related local complications (n) | 146 (16.7%) | 872 | 318 (16.5%) | 1932 | 0.852 |
| Non-infection-related complications requiring revision surgery (n) | 24 (2.9%) | 820 | 58 (3.1%) | 1876 | 0.819 |

* Statistically significant. Abbreviations: RCT, randomized controlled trial; PCCS, prospective comparative cohort study; RCCS, retrospective comparative cohort study; PCS, prospective case series; RCS, retrospective case series; CoNS, coagulase-negative staphylococci; PJI, periprosthetic joint infection; FU, follow-up; KSS, Knee Society Score; HSS, Hospital for Special Surgery Knee-Rating Scale.

Table 4. Correlations between time to second stage and outcomes.

| Static | Articulated | Total | Spacers with Data Available (n) |
|--------|-------------|-------|---------------------------------|
| Rho | p-Value | Rho | p-Value | Rho | p-Value | Rho | p-Value |
| PJI recurrence (n) | 0.040 | 0.876 | 0.274 | 0.040 * | 0.202 | 0.082 | 2786 | |
| Mean time to PJI recurrence | 0.5 | 0.391 | -0.772 | 0.072 | 0.092 | 0.789 | 474 |
| Mean active knee flexion at last FU | -0.080 | 0.595 | -0.361 | 0.019 * | -0.257 | 0.050 * | 1656 | |
| Mean KSS score at last FU | -0.267 | 0.455 | -0.073 | 0.759 | -0.147 | 0.438 | 956 | |

* Statistically significant. Abbreviations: PJI, periprosthetic joint infection; KSS, Knee Society Score; FU, follow-up.
Mean active knee flexion at last FU
Mean time to PJI recurrence

Peri-operative non-infection-related local complications
Mean HSS score at last FU

No reimplantation (n) 67 (7.1%) 947 94 (4.3%) 2198 0.001 *

Figure 3. Forest plot of overall meta-analysis evaluating comparative studies (static spacers vs. articulated spacers) with data about PJI recurrences [21,23–25,29–31,34,38,39,43,44,46–48,50,52,54] (a), active knee flexion at last follow-up (b), and non-infection-related peri-operative local complications (c). Abbreviations: ES, effect size; 95% CI, 95% confidence interval; W, weight; V, variance; SE, standard error; N, sample size; N1, static spacer series sample size; N2, articulated spacer series sample size.

Figure 4. Funnel plot of effect sizes for publication bias of the comparative studies evaluating PJI recurrences (a), active knee flexion at last follow-up (b), and non-infection-related peri-operative local complications (c).
3. Results

A total of 3421 studies were found through the electronic search and 21 studies were added after the cross-referenced research on the bibliographies of the examined full-text articles. After a preliminary analysis, a total of 87 studies reporting series of knee spacers used for two-stage treatment of PJI were included in this systematic review (1 randomized controlled trial, 3 prospective comparative cohort studies, 26 retrospective comparative cohort studies, 9 prospective case series, 48 retrospective case series [18–102] (Tables 1 and 2; Figure 1)). Among these, eighteen studies were included in the meta-analysis (Figures 3 and 4). Studies comparing static vs. articulated spacers were 1 RCT [43], 1 PCCS [22], and 16 RCCS [18,20,21,26–28,31,35,36,41,43–45,47,49,51]. In total, 34 series on static spacers [18–51] and 71 on articulated spacers [18,20,21,26–28,31,35,36,41,43–45,47,49,51–102] were found (Figure 3).

The overall quality of the studies included in the meta-analysis, assessed by the RoB2 and the ROBINS-I tools [16,17], was high in only one case [40], moderate in 6 cases [22,27,35,36,45,49], and low in 11 cases [18,20,21,26,28,31,41,43,44,47,51] (Figure 2a–c). A total of 4250 knee spacers were included: 1511 static spacers and 2739 articulated spacers (Table 3). The two groups were highly homogeneous considering a number of variables (Table 3). Mean age was comparable between static and articulated series (67 ± 5.6 years and 66.4 ± 3.5, respectively; p = 0.532) (Table 3). No statistical difference was found between the two groups also concerning the mean follow-up (68 ± 52.3 months for static group and 53.5 ± 32.9 months for articulated group; p = 0.117) (Table 3). The most frequent bacterial populations found were *Staphylococcus aureus*, *Streptococcus epidermidis*, and other coagulase-negative staphylococci in both groups (Table 3). Mean time to PJI onset from primary arthroplasty surgery was also similar (34.8 ± 14.3 months for static group and 36.8 ± 11.9 months for articulated group; p = 0.735) (Table 3). No significant difference was found in the time between first and second stage (3.1 ± 1.1 months for static group and 3.6 ± 2.3 months for articulated group; p = 0.480), nor in the number of spacer exchanges with repeated first stage before reimplantation (5.4% vs. 4% for static and articulated series, respectively; p = 0.159) (Table 3). Instead, a mismatch was found between the two groups in the mean duration of post-operative antibiotic therapy after first-stage surgery, being longer for static spacers (7.2 ± 1.9 vs. 6.1 ± 1 weeks; p = 0.007) (Table 3).

With respect to the results in terms of infection control, a significantly higher rate of both no reimplantation and PJI recurrence was found when static spacers were used. In detail, a revision knee arthroplasty was not performed in 7.1% of the PJIs in the static spacer group and in 4.3% of the cases in the articulated group (p = 0.001), while PJI recurrence was found in 12.4% vs. 9% of the two-stage procedures (p = 0.001) (Table 3). The time elapsed between the first and second stage appeared to directly influence the PJI recurrence rate (with a trend towards more recurrences in the case of longer time with a spacer in situ), although a significant correlation was only found for articulated spacers (p = 0.040) (Table 4). The meta-analysis performed on comparative studies evaluating the PJI recurrence with static vs. articulated spacers confirmed a trend for better infection control using articulated spacers, although no significant difference was found between the groups (p = 0.530) (Figure 3a). No significative heterogeneity (I² ≈ 0%, p = 0.992) or relevant publication bias (Figure 4a) was found regarding the PJI recurrence rate. No significant difference was found concerning the mean time to PJI recurrence between static and articulated spacers (13.7 ± 3.9 months and 23.2 ± 12.1 months, respectively; p = 0.125) (Table 3). Furthermore, no correlations between the mean time to second stage after spacer placement and the mean time to PJI recurrence were found (Table 4).

With regard to the functional outcomes, mean active knee flexion at last follow-up was found to be significantly higher using articulated spacers (91.6° ± 7° for static spacers vs. 100.3° ± 9.9° for articulated spacers; p < 0.001) (Table 3). The meta-analysis also confirmed this strong significant difference (p < 0.001) (Figure 3b). Moderate heterogeneity (I² = 69.1%, p = 0.059) and no relevant publication bias (Figure 4b) were found regarding the active knee flexion. A significant negative correlation was found between the mean time to second
stage after spacer placement and the mean final active knee flexion, which appeared to be particularly marked when using articulated spacers ($p = 0.019$) (Table 4). However, when clinical scores were considered (KSS and HSS), no significant difference was found between static and articulated groups (81.1 ± 13.1 vs. 81.9 ± 5.5 for KSS, $p = 0.792$; 81.8 ± 0.7 vs. 81.7 ± 7 for HSS, $p = 0.981$) (Table 3).

No difference was found regarding the incidence of peri-operative local complications not related to the PJI between static and articulated spacers (complication rate: 16.7% vs. 16.5%; $p = 0.852$) (Table 3). The revision rate for non-infection-related complications was found to be also similar between static and articulated spacers (2.9% vs. 3.1%; $p = 0.819$) (Table 3). The meta-analysis did not find significant differences between the groups either ($p = 0.573$) (Figure 3c). Low heterogeneity ($I^2 = 41.3\%, p = 0.099$) and no relevant publication bias (Figure 4c) were found regarding the complication rate.

4. Discussion

Both static and articulated antibiotic-laden spacers have benefits and drawbacks, and the choice is based on multiple factors, including the clinical assessment of the patient’s general functional status, general health, soft tissue envelope of the knee, virulence of the organism, and extent of bone loss [107]. The existing literature on the subject largely consists of small series with evidence levels III and IV and a limited number of randomized prospective trials.

In this review, we found, in the pooled analysis, a significantly lower number of PJI recurrences when an articulated spacer was used. This trend was also found in the meta-analysis of the comparative studies alone, though without a statistically significant difference. No significant differences were found either in the number of non-infection-related complications or in the functional results from the evaluation of the HSS and KSS scores, as already reported by previous studies [11].

Conversely, a strong difference emerged in favor of articulated spacers, both in the general pooled data analysis and the meta-analysis of comparative studies, regarding active knee flexion capability at the last follow-up after prosthesis reimplantation.

The main benefit of articulated spacers is that they enable movement of the joint between surgeries. Articulated spacers also allow a more comfortable position of the knee during sitting, standing, and car travel. Maintaining motion facilitates the recovery of limb function during treatment of infection. Knee flexion preserves the length and elasticity of the extensor mechanism and helps to prevent scarring of the soft tissue around the joint and capsular stiffening [96,108,109]. As a result, the extent of surgical exposure required and the overall difficulty of the second-stage surgery can be decreased [26,34,109]. Moreover, the findings of an in vitro study showed that cyclical loading of the cement spacers enhanced the elution of vancomycin and tobramycin [110]. A broad assortment of articulated spacers that can be placed after the removal of an infected total knee arthroplasty is available—for example, (1) handmade cement-on-cement spacers without molds, (2) premolded or preformed antibiotic cement spacers (with or without stems), (3) surgical molds for intraoperative fabrication (with or without metal femoral runners), and (4) autoclaved or new metal femoral and polyethylene components (Table 1) [111]. Most of the articulated spacers included in this study were found to be cement-on-cement spacers. Consequently, no further investigation was performed to reveal whether there are differences in outcomes depending on the subtype of mobile spacer.

Common indications for use of a static spacer are (1) patients with severe uncontrolled infections; (2) ligamentous laxity, particularly in the case of collateral ligament compromise, as an articulated spacer would not allow for multiplanar knee stability; (3) extensor mechanism disruption or insufficiency, as active flexion and control of the knee would not be achieved; (4) compromised soft tissue coverage over the joint, since motion might apply additional tension; (5) severe bone loss after prosthesis explant, as they can be customized to fill the gap and eventually stabilized using intramedullary dowels [9,108,109,112–114]. Moreover, static spacers are usually cheaper [115,116].
However, several shortcomings of static spacers have been suggested. Several studies have reported poor limb mobility with static spacers after reimplantation compared to articulated spacers [108,117,118]. In addition, unanticipated bone loss as a result of spacer migration has been observed. Using static spacers may also complicate exposure during the second-stage procedure due to the shortening of the ligaments and quadriceps, as well as wound closure [29].

A factor that is difficult to standardize within the two-stage protocol is the time of spacer persistence, before reimplantation. Longer intervals between the two stages are known to correlate with worse infectious and functional outcomes [7,119,120]. Elution of the antibiotic from any spacer reaches its peak in the first 72 h from placement: after this time, the function of any is mainly mechanical [13,121]. Moreover, a longer time of spacer persistence may increase the incidence of mechanical complications such as spacer rupture or dislocation, which can eventually lead to an interim spacer exchange [122].

We observed that, in the case of articulated spacers, a spacer persistence of more than 3 weeks increased the number of PJI recurrences. Furthermore, it was found that spacer persistence progressively decreases the ability of articulated spacers to preserve active flexion.

It was not possible to perform a detailed analysis of any inconsistencies in terms of the surgical and infectious complexity of the cases in order to exclude any selection bias whereby the more complex cases were preferentially treated with a static spacer. For example, the study by Guild et al., analyzing data on the existence of bone loss of any type, found no statistical difference in the placement of static vs. articulating spacers for the indication of bone loss [11]. However, when they classified bone loss according to the Anderson Orthopaedic Research Institute (AORI) classification [123], they found that static spacers were placed significantly more frequently for femoral bone loss than articulated spacers [11]. These data, however, may be biased as only a small minority of the studies specifically addressed pre-existing bone loss. However, not only bone deficiency has to be considered when assessing complexity. It depends on many other factors (type of microorganism, quality of soft tissue, comorbidity, etc.), and even within individual studies, it was almost never possible to effectively differentiate cases by complexity. A possible patient selection bias among the included studies represents the major limitation of this study. A previous review by Pivec et al. attempted to divide patients with an articulated spacer into complex and non-complex cases and compared the results between these two subgroups and patients with a static spacer [124]. They reported a slightly higher PJI recurrence rate in the articulated spacer group with only complex patients compared to the static spacer group, but no statistical significance was shown [124]. In the present review, considering the wide variability of the criteria used in the individual studies and the paucity of studies in which the individual patients could be characterized, we decided not to perform such an analysis. However, this review only considered primary infections, so it is reasonable to assume that tremendously destructive conditions of the knee that are unsuitable for dynamic spacers are a minority and probably not crucial in the interpretation of the overall emerging findings, also considering the high number of spacers included in this review. Unfortunately, only high-quality studies, with accurate assessment to ensure the homogeneity of patient selection, can help to solve this issue. A review, although systematic, can only state that it is reasonable to believe that the use of articulated spacers should definitely be considered in all cases where there are no significant contraindications, as it offers excellent results with respect to infection control and functional outcomes, with complications comparable to those expected with the use of static spacers. Unfortunately, it is difficult to establish the limit beyond which the use of a static spacer can guarantee greater benefit.

Among the limitations of this article, in addition to those already mentioned, the average low quality of the studies (for the majority consisting of case series or retrospective comparative studies) must be considered. In addition, this is certainly not the first review on the topic and essentially confirms evidence that has already emerged. The main strength
is the amount of data collected and the depth of the analysis. In fact, to the best of our knowledge, it is the first review to provide a large-scale quantitative analysis. These aspects make it a very comprehensive and up-to-date review on the subject and reinforce the conclusion that only high-quality studies can clarify the elements still under discussion.

5. Conclusions

In conclusion, this review confirms that articulated spacers do not appear to be inferior to static spacers in terms of infection control, complications, and functional results, while they are superior in terms of active flexion granted after reimplantation. Static spacers, often mostly used in more severe cases, can offer similar infection control in this scenario. However, despite the high number of included spacers, considering the average low quality of the studies included and the impossibility of determining the presence and extent of a selection bias in the choice of the spacers, it is not possible to generalize the results that emerged. Nevertheless, in cases that meet all the appropriate conditions for the placement of articulated spacers, optimal results can be expected, and their use can be recommended.

Author Contributions: Conceptualization, M.F. (Michele Fiore) and A.S.; methodology, M.F. (Michele Fiore); software, M.F. (Matteo Filippini); investigation, M.F. (Matteo Filippini) and L.M.; data curation, C.R. and A.P.; writing—original draft preparation, M.F. (Michele Fiore), M.F. (Matteo Filippini), L.M., R.Z. and C.G.; writing—review and editing, M.F. (Michele Fiore) and A.S.; supervision, P.V. and M.D.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data reported in this study are available in the literature.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Gehrke, T.; Alijanipour, P.; Parvizi, J. The management of an infected total knee arthroplasty. Bone Jt. J. 2015, 97, 20–29. [CrossRef] [PubMed]
2. Lamagni, T. Epidemiology and burden of prosthetic joint infections. J. Antimicrob. Chemother. 2014, 69 (Suppl. 1), i5–i10. [CrossRef] [PubMed]
3. Sambri, A.; Fiore, M.; Tedeschi, S.; De Paolis, M. The Need for Multidisciplinarity in Modern Medicine: An Insight into Orthopaedic Infections. Microorganisms 2022, 10, 756. [CrossRef] [PubMed]
4. Calanna, F.; Chen, F.; Risitano, S.; Vorhies, J.S.; Franceschini, M.; Giori, N.J.; Indelli, P.F. Debridement, antibiotic pearls, and retention of the implant (DAPRI): A modified technique for implant retention in total knee arthroplasty PJI treatment. J. Orthop. Surg. 2019, 27, 2309499019874413. [CrossRef]
5. Parvizi, J.; Tan, T.L.; Goswami, K.; Higuera, C.; Della Valle, C.; Chen, A.E.; Shohat, N. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J. Arthroplast. 2018, 33, 1309–1314.e2. [CrossRef] [PubMed]
6. Osmon, D.R.; Berbari, E.F.; Berendt, A.R.; Lew, D.; Zimmerli, W.; Steckelberg, J.M.; Rao, N.; Hanssen, A.; Wilson, W.R.; Infectious Diseases Society of, A. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2013, 56, e1–e25. [CrossRef] [PubMed]
7. Izakovcicova, P.; Borens, O.; Trampuz, A. Periprosthetic joint infection: Current concepts and outlook. EFORT Open Rev. 2019, 4, 482–494. [CrossRef]
8. Masters, J.P.; Smith, N.A.; Foguet, P.; Reed, M.; Parsons, H.; Sproson, A.P. A systematic review of the evidence for single stage and two stage revision of infected knee replacement. BMC Musculoskelet. Disord. 2013, 14, 222. [CrossRef]
9. Charette, R.S.; Melnic, C.M. Two-Stage Revision Arthroplasty for the Treatment of Prosthetic Joint Infection. Curr. Rev. Musculoskelet. Med. 2018, 11, 332–340. [CrossRef]
10. Sambri, A.; Bianchi, G.; Parry, M.; Frenos, F.; Campanacci, D.; Donati, D.; Jeys, L. Is Arthrodesis a Reliable Salvage Option following Two-Stage Revision for Suspected Infection in Proximal Tibial Replacements? A Multi-Institutional Study. J. Knee Surg. 2018, 32, 911–918. [CrossRef]
11. Guild, G.N., III; Wu, B.; Scuderi, G.R. Articulating vs. Static antibiotic impregnated spacers in revision total knee arthroplasty for sepsis. A systematic review. J. Arthroplast. 2014, 29, 558–563. [CrossRef] [PubMed]
12. Anagnostakos, K.; Fink, B. Antibiotic-loaded cement spacers—Lessons learned from the past 20 years. Expert Rev. Med. Devices 2018, 15, 231–245. [CrossRef] [PubMed]
39. Kong, L.; Mei, J.; Ge, W.; Jin, X.; Chen, X.; Zhang, X.; Zhu, C. Application of 3D Printing-Assisted Articulating Spacer in Two-Stage Revision Surgery for Periprosthetic Infection after Total Knee Arthroplasty: A Retrospective Observational Study. BioMed Res. Int. 2021, 2021, 3948638. [CrossRef]

40. Lichtstein, P.; Su, S.; Hedlund, H.; Suh, G.; Maloney, W.J.; Goodman, S.B.; Huddleston, J.I. III. Treatment of Periprosthetic Knee Infection with a Two-stage Protocol Using Static Spacers. Clin. Orthop. Relat. Res. 2016, 474, 120–125. [CrossRef]

41. Lo Presti, M.; Costa, G.G.; Vascio, C.; Agrò, G.; Poggi, A.; Neri, M.P.; Zaffagnini, S. Küntscher nails with static cement spacer: A simple technique in periprosthetic knee infections with massive bone loss and instability. Knee 2021, 29, 580–588. [CrossRef] [PubMed]

42. Ma, H.H.; Chou, T.A.; Tsai, S.W.; Chen, C.F.; Wu, P.K.; Chen, C.M.; Chen, W.M. Is short-course systemic antibiotic therapy using an antibiotic-loaded cement spacer safe after resection for infected total knee arthroplasty? A comparative study. J. Formos. Med. Assoc. 2019, 119, 1070–1079. [CrossRef] [PubMed]

43. Nahhas, C.R.; Chalmers, P.N.; Parvizi, J.; Sporer, S.M.; Berend, K.R.; Moric, M.; Chen, A.F.; Austin, M.S.; Deirmengian, G.K.; Morris, M.J. et al. A Randomized Trial of Static and Articulating Spacers for the Treatment of Infection Following Total Knee Arthroplasty. J. Bone Jt. Surg. Am. 2020, 102, 778–787. [CrossRef]

44. Park, S.J.; Song, E.K.; Seon, J.K.; Yoon, T.R.; Park, G.H. Comparison of static and mobile antibiotic-impregnated cement spacers for the treatment of infected total knee arthroplasty. Int. Orthop. 2010, 34, 1181–1186. [CrossRef] [PubMed]

45. Petis, S.M.; Perry, K.I.; Mabry, T.M.; Hanssen, A.D.; Berry, D.J.; Abdel, M.P. Two-Stage Exchange Protocol for Periprosthetic Joint Infection Following Total Knee Arthroplasty in 245 Knees without Prior Treatment for Infection. J. Bone Jt. Surg. Am. 2019, 101, 239–249. [CrossRef] [PubMed]

46. Pirobranzhensky, P.M.; Bozhkova, S.A.; Kazemirsky, A.V.; Tikhilov, R.M.; Kulaba, T.A.; Kornilov, N.N. Functional outcome of two-stage reimplantation in patients with periprosthetic joint infection after primary total knee arthroplasty. Int. Orthop. 2019, 43, 2500–2509. [CrossRef]

47. Rossi, S.M.P.; Medetti, M.; Perticarini, L.; Ghiara, M.; Benazzo, F. Customized intraoperatively molded articulating cement spacers for two-stage revisions TKA with major bone defects. Eur. J. Orthop. Surg. Traumatol. 2021, 31, 1121–1128. [CrossRef]

48. Schneider, A.M.; Holzmeister, A.M.; Frazzett, A.J.; Adams, W.; Hopkinson, W.J.; Brown, N.M. New Primary Total Knee Arthroplasty Components Versus Other Contemporary Types of Spacers for the Treatment of Chronic Periprosthetic Knee Infection with a Two-Stage Protocol. Clin. Orthop. Relat. Res. 2022, 455, 109–115. [CrossRef]

49. Silvestre, A.; Almeida, F.; Renovell, P.; Morante, E.; López, R. Revision of infected total knee arthroplasty: Two-stage reimplantation using an antibiotic-impregnated static spacer. Clin. Orthop. Surg. 2015, 3, 180–187. [CrossRef] [PubMed]

50. Skwara, A.; Tisbescu, C.; Paletta, R.J.; Sommer, C.; Krödel, A.; Lahner, M.; Danilidis, K. Articulating spacers compared to fixed spacers for the treatment of infected knee arthroplasty. Technol. Health Care 2016, 24, 571–577. [CrossRef]

51. Springer, B.D.; Lee, G.C.; Osmon, D.; Haidukewych, G.J.; Hanssen, A.D.; Jacofsky, D.J. Systemic safety of high-dose antibiotic-impregnated cement spacers after resection of an infected total knee arthroplasty. Clin. Orthop. Relat. Res. 2004, 427, 47–51. [CrossRef]

52. Vasarhelyi, E.; Sidhu, S.P.; Somerville, L.; Lanting, B.; Naudie, D.; Howard, J. Static vs. Articulating Spacers for Two-Stage Revision Total Knee Arthroplasty: Minimum Five-Year Review. Arthroplast. Today 2022, 13, 171–175. [CrossRef] [PubMed]

53. Vielgut, I.; Schwantzer, G.; Leitner, A.; Sadoghi, P.; Berzens, U.; Glehr, M. Successful Two-Stage Exchange Arthroplasty for Periprosthetic Infection Following Total Knee Arthroplasty: The Impact of Timing on Eradication of Infection. Int. J. Med. Sci. 2021, 18, 1000–1006. [CrossRef]

54. Zamora, T.; Garbuz, D.S.; Greidanus, N.V.; Masri, B.A. An articulated spacer made of new primary implants in two-stage revision surgery for infected total knee arthroplasty may provide durable results. Bone Jt. J. 2020, 102, 852–860. [CrossRef] [PubMed]

55. Ahmad, S.S.; Huber, K.; Evangelopoulos, D.S.; Kleer, B.; Kohlhof, H.; Schön, M.; Eggli, S.; Kohl, S. The cement prosthesis-like spacer: An intermediate halt on the road to healing. Sci. World J. 2013, 2013, 763434. [CrossRef]

56. Babis, G.C.; Zahos, K.A.; Tsialas, P.; Karaliotas, G.I.; Kanellakopoulou, K.; Sourcos, P.N. Treatment of stage III-A-1 and III-B-1 periprosthetic knee infection with two-stage exchange arthroplasty and articulating spacer. J. Surg. Orthop. Adv. 2008, 17, 173–178. [CrossRef] [PubMed]

57. Boelch, S.P.; Jakuscheit, A.; Luedemann, M.; Heilig, P.; Kamawal, A.; Arnholdt, J.; Rudert, M. Do not exchange the spacer during staged TKA exchange! J. Orthop. 2021, 23, 41–45. [CrossRef]

58. Buyuk, A.F.; Sofu, H.; Camurcu, I.Y.; Ucplaran, H.; Kaygusuq, M.A.; Sahin, V. Can Teicoplanin Be an Effective Choice for Antibiotic-Impregnated Cement Spacer in Two-Stage Revision Total Knee Arthroplasty? J. Knee Surg. 2017, 30, 283–288. [CrossRef] [PubMed]

59. Carulli, C.; Villano, M.; Cividini, R.; Matassi, F.; Nistri, L.; Innocenti, M. A novel technique to preserve range of motion in two-stage revision of infected total knee arthroplasty. Int. Orthop. 2013, 37, 1069–1074. [CrossRef]

60. Castelli, C.C.; Gotti, V.; Ferrari, R. Two-stage treatment of infected total knee arthroplasty: Two to thirteen year experience using an articulating preformed spacer. Int. Orthop. 2014, 38, 405–412. [CrossRef]

61. Durbhakula, S.M.; Czaikaj, J.; Fuchs, M.D.; Uhl, R.L. Antibiotic-loaded articulating cement spacer in the 2-stage exchange of infected total knee arthroplasty. J. Arthroplast. 2004, 19, 768–774. [CrossRef] [PubMed]

62. Evans, R.P. Successful treatment of total hip and knee infection with articulating antibiotic components: A modified treatment method. Clin. Orthop. Relat. Res. 2004, 427, 37–46. [CrossRef] [PubMed]

63. Fei, Z.; Zhang, Z.; Wang, Y.; Zhang, H.; Xiang, S. Comparing the Efficacy of Articulating Spacers in Two-Stage Revision for Periprosthetic Joint Infection Following Total Knee Arthroplasty: All-Cement Spacers vs. Sterilized Replanted Metal-Polyethylene Spacers. Int. J. Gen. Med. 2022, 15, 3293–3301. [CrossRef] [PubMed]
64. Garg, P.; Ranjan, R.; Bandyopadhyay, U.; Chouksey, S.; Mitra, S.; Gupta, S.K. Antibiotic-impregnated cementing spacer for infected total knee arthroplasty. Indian J. Orthop. 2011, 45, 535–540. [CrossRef] [PubMed]

65. Ghanem, M.; Pempe, C.; Zajonz, D.; Roth, A.; Heyde, C.E.; Josten, C. Mid-term results of two-stage revision of total knee arthroplasty using a mobile (dynamic) cement spacer in the treatment of periprosthetic infections. GMS Interdiscip. Plast. Reconstr. Surg. DCPW 2018, 7, Doc02. [CrossRef] [PubMed]

66. Gooding, C.R.; Masri, B.A.; Duncan, C.P.; Greidanus, N.V.; Garbuz, D.S. Durable infection control and function with the PROSTALAC spacer in two-stage revision for infected knee arthroplasty. Clin. Orthop. Relat. Res. 2011, 469, 985–993. [CrossRef] [PubMed]

67. Ha, C.W. A technique for intraoperative construction of antibiotic spacers. Clin. Orthop. Relat. Res. 2006, 445, 204–209. [CrossRef]

68. Haddad, F.S.; Masri, B.A.; Campbell, D.; McGraw, R.W.; Beauchamp, C.P.; Duncan, C.P. The PROSTALAC functional spacer in two-stage revision for infected knee replacements. Prosthesis of antibiotic-loaded acrylic cement. J. Bone Jt. Surg. Br. 2000, 82, 807–812. [CrossRef]

69. Hammerich, K.; Pollack, J.; Hasse, A.F.; El Saman, A.; Huber, R.; Rupp, M.; Alt, V.; Kinne, R.W.; Mika, J. The Inverse Spacer-A Novel, Safe, and Cost-Effective Approach in Revision Knee Arthroplasty. J. Clin. Med. 2021, 10, 971. [CrossRef]

70. Hart, W.J.; Jones, R.S. Two-stage revision of infected total knee replacements using articulating cement spacers and short-term antibiotic therapy. J. Bone Jt. Surg. Br. 2006, 88, 1011–1015. [CrossRef]

71. Hoshino, T.; Watanabe, T.; Nakagawa, Y.; Katagiri, H.; Ozeki, N.; Ohara, T.; Shioda, M.; Kono, Y.; Sekiya, I.; Koga, H. Clinical outcomes of two-stage revision total knee arthroplasty in infected cases with antibiotic-loaded cement spacers produced using a handmade silicone mold. Knee Surg. Relat. Res. 2021, 33, 27. [CrossRef] [PubMed]

72. Incavo, S.J.; Russell, R.D.; Mathis, K.B.; Adams, H. Initial results of managing severe bone loss in infected total joint arthroplasty using customized articulating spacers. J. Arthroplast. 2009, 24, 607–613. [CrossRef]

73. Jia, Y.T.; Zhang, Y.; Ding, C.; Zhang, N.; Zhang, D.L.; Sun, Z.H.; Tian, M.Q.; Liu, J. Antibiotic-loaded articulating cement spacers in two-stage revision for infected total knee arthroplasty: Individual antibiotic treatment and early results of 21 cases. Chin. J. Traumatol. 2012, 15, 212–221.

74. Jung, K.H.; Lee, C.C.; Kim, T.H.; Han, J.W.; Park, K.B. Does spikd tibial cement spacer reduce spacer-related problems in two-stage revision total knee arthroplasty for infection? Int. Orthop. 2022, 46, 2009–2017. [CrossRef]

75. Kalore, N.V.; Maheshwari, A.; Sharma, A.; Cheng, E.; Goe, T. Is there a preferred articulating spacer technique for infected knee arthroplasty? A preliminary study. Clin. Orthop. Relat. Res. 2012, 470, 228–235. [CrossRef]

76. Kohl, S.; Evangelopoulos, D.S.; Kohlhof, H.; Krueger, A.; Hartel, M.; Roeder, C.; Eggli, S. An intraoperatively moulded PMMA prostheses like spacer for two-stage revision of infected total knee arthroplasty. Knee 2011, 18, 464–469. [CrossRef]

77. Lin, T.L.; Tsai, C.H.; Fong, Y.C.; Shie, M.Y.; Chen, H.Y.; Chen, Y.W. Cruciate-Retaining vs Posterior-Stabilized Antibiotic Cement prostheses like spacer for two-stage revision of infected total knee arthroplasty. J. Arthroplast. 2021, 36, 3750–3759. [CrossRef] [PubMed]

78. Lu, J.; Han, J.; Zhang, C.; Yao, Z.; Yang, Y. Polyethylene on Cement Spacers: An Economic Approach to an Effective Infection Eradication in a Two-Stage Knee Revision Articulating Spacers. J. Knee Surg. 2018, 31, 986–991. [CrossRef]

79. MacAvoy, M.C.; Ries, M.D. The ball and socket articulating spacer for infected total knee arthroplasty. J. Arthroplast. 2005, 20, 757–762. [CrossRef]

80. MacAvoy, M.C.; Ries, M.D. The ball and socket articulating spacer for infected total knee arthroplasty. J. Arthroplast. 2005, 20, 757–762. [CrossRef]

81. Marothi, D.P.; Sharma, V.; Sheth, A.N.; Shah, V.I.; Bharath, L.; Pachore, J.A. Management of Infected Total Knee Arthroplasty by a New Innovative Customized Articulating Knee Spacer: An Early Experience. J. Orthop. Case Rep. 2016, 6, 20–22. [CrossRef] [PubMed]

82. Mutimer, J.; Gillespie, G.; Lovering, A.M.; Porteous, A.J. Measurements of in vivo intra-articular gentamicin levels from antibiotic loaded articulating spacers in revision total knee replacement. Knee 2009, 16, 39–41. [CrossRef] [PubMed]

83. Ogudur, A.; Firat, A.; Tecimel, O.; Solak, S.; Bozkurt, M. Two-stage total infected knee arthroplasty treatment with articulating cement spacer. Arch. Orthop. Trauma. Surg. 2010, 130, 719–725. [CrossRef]

84. Ortola, D.J.; Fenga, D.; Marcellino, S.; Rosi, M.; Centofanti, F.; Rosa, M.A. Peri-Prosthetic Knee Infection Management: Spacers Loaded with Two or Three Antibiotic Agents. Surg. Infect. 2017, 18, 619–624. [CrossRef] [PubMed]

85. Pascale, V.; Pascale, W. Custom-made articulating spacer in two-stage revision total knee arthroplasty. An early follow-up of 14 cases of at least 1 year after surgery. HSS J. 2007, 3, 159–163. [CrossRef] [PubMed]

86. Pitt, R.P.; Castelli, C.C.; Ferrari, R.; Munro, J. Pre-formed articulating knee spacer in two-stage revision for the infected total knee arthroplasty. Int. Orthop. 2005, 29, 305–308. [CrossRef]

87. Radoicic, D.; Milanovic, M.; Marinkovic, J.; Radoicic, D. Ertapenem Articulating Spacer for the Treatment of Polymicrobial Total Knee Arthroplasty Infection. Can. J. Infect. Dis. Med. Microbiol. 2016, 2016, 5753489. [CrossRef]

88. Roof, M.A.; Baylor, J.L.; Bernstein, J.A.; Antonelli, B.J.; Kugelman, D.N.; Egel, A.J.; Melnic, C.M.; Chen, A.F.; Long, W.J.; Aggarwal, V.K.; et al. Comparing the Efficacy of Articulating Spacer Constructs for Knee Periprosthetic Joint Infection Eradication: All-Cement vs Real-Component Spacer. J. Arthroplast. 2021, 36, S320–S327. [CrossRef]
101. Vasso, M.; Del Regno, C.; Corona, K.; D'Apolito, R.; Schiavone Panni, A. Articulated spacer provides long-term knee improvement.

97. Tian, M.Q.; Yang, X.T.; Tian, X.B.; Sun, Y.B.; Duan, Y.H.; Sun, L. Short-term Follow-up of Antibiotic-loaded Articulating Cement.

93. Siebel, T.; Kelm, J.; Porsch, M.; Regitz, T.; Neumann, W.H. Two-stage exchange of infected knee arthroplasty with an prosthesis-like articulating spacer for infected total knee arthroplasty. Knee 2010, 17, 407–411. [CrossRef]

94. Struelens, B.; Claes, S.; Bellemans, J. Spacer-related problems in two-stage revision knee arthroplasty. Acta Orthop. Belg. 2002, 68, 150–156.

109. Lu, J.; Han, J.; Zhang, X.; Jiang, Y.; Wang, Q.; Chen, Y.; Wang, Q.; Shao, J. Intraoperatively-made cement-on-cement antibiotic-loaded articulating spacer for infected total knee arthroplasty. Knee 2010, 17, 407–411. [CrossRef]

112. Hasandoost, L.; Rodriguez, O.; Alhalawani, A.; Zalzal, P.; Schemitsch, E.H.; Waldman, S.D.; Papini, M.; Towler, M.R. The Role of Poly(Methyl Methacrylate) in Management of Bone Loss and Infection in Revision Total Knee Arthroplasty: A Review. J. Funct. Biomater. 2020, 11, 25. [CrossRef] [PubMed]

110. Rogers, B.A.; Middleton, F.R.; Shearwood-Porter, N.; Kinch, S.; Roques, A.; Bradley, N.W.; Browne, M. Does cyclical loading affect the elution of antibiotics from articulating cement knee spacers? Clin. Orthop. Relat. Res. 2015, 472, 2201–2207. [CrossRef] [PubMed]

106. Zielinski, M.R.; Ziemba-Davis, M.; Warth, L.C.; Keyes, B.J.; Meneghini, R.M. Do Antibiotic Intramedullary Dowels Assist in Eradicating Infection in Two-Stage Resection for Septic Total Knee Arthroplasty? J. Arthroplasty 2015, 30, 755–761. [CrossRef] [PubMed]

89. Sakellariou, V.I.; Savvidou, O.; Markopoulos, C.; Drakou, A.; Mavrogenis, A.F.; Papagelopoulos, P.J. Combination of Calcium Hydroxyapatite Antibiotic Carrier with Cement Spacers in Peri-Prosthetic Knee Infections. Surg. Infect. 2015, 16, 748–754. [CrossRef]

90. Seo, S.S.; Kim, C.W.; Lee, C.R.; Park, D.H.; Kwon, Y.U.; Jung, D.; Kim, D.S. Clinical outcomes of two-stage total knee arthroplasty using articulating cement spacer in patients with infected arthritic knee: A comparison with arthroscopic surgery. Knee 2020, 27, 444–450. [CrossRef]

91. Su, Y.P.; Lee, O.K.; Chen, W.M.; Chen, T.H. A facile technique to make articulating spacers for infected total knee arthroplasty. J. Chin. Med. Assoc. 2009, 72, 138–145. [CrossRef]

92. Shen, H.; Zhang, X.; Jiang, Y.; Wang, Q.; Chen, Y.; Wang, Q.; Shao, J. Intraoperatively-made cement-on-cement antibiotic-loaded articulating spacer for infected total knee arthroplasty. Knee 2010, 17, 407–411. [CrossRef]
115. Antoci, V.; Phillips, M.J.; Antoci, V., Jr.; Krackow, K.A. Using an antibiotic-impregnated cement rod-spacer in the treatment of infected total knee arthroplasty. *Am. J. Orthop.* 2009, 38, 31–33. [PubMed]

116. Jiranek, W.A.; Hanssen, A.D.; Greenwald, A.S. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. *J. Bone Jt. Surg. Am.* 2006, 88, 2487–2500. [CrossRef]

117. Kalore, N.V.; Goe, T.J.; Singh, J.A. Diagnosis and management of infected total knee arthroplasty. *Open Orthop. J.* 2011, 5, 86–91. [CrossRef]

118. Jacobs, C.; Christensen, C.P.; Berend, M.E. Static and mobile antibiotic-impregnated cement spacers for the management of prosthetic joint infection. *J. Am. Acad. Orthop. Surg.* 2009, 17, 356–368. [CrossRef]

119. Golgelioglu, F.; Oguzkaya, S.; Misir, A.; Guney, A. The Effect of Time Spent with a Dynamic Spacer on Clinical and Functional Outcomes in Two-Stage Revision Knee Arthroplasty. *Indian J. Orthop.* 2020, 54, 824–830. [CrossRef]

120. Vielgut, I.; Sadoghi, P.; Wolf, M.; Holzer, L.; Leithner, A.; Schwantzer, G.; Poolman, R.; Frankl, B.; Glehr, M. Two-stage revision of prosthetic hip joint infections using antibiotic-loaded cement spacers: When is the best time to perform the second stage? *Int. Orthop.* 2015, 39, 1731–1736. [CrossRef]

121. Klinder, A.; Zaatreh, S.; Ellenrieder, M.; Redanz, S.; Podbielski, A.; Reichel, T.; Bösebeck, H.; Mittelmeier, W.; Bader, R. Antibiotics release from cement spacers used for two-stage treatment of implant-associated infections after total joint arthroplasty. *J. Biomed. Mater. Res. B Appl. Biomater.* 2019, 107, 1587–1597. [CrossRef] [PubMed]

122. Tan, T.L.; Goswami, K.; Kheir, M.M.; Xu, C.; Wang, Q.; Parvizi, J. Surgical Treatment of Chronic Periprosthetic Joint Infection: Fate of Spacer Exchanges. *J. Arthroplast.* 2019, 34, 2085–2090. [CrossRef] [PubMed]

123. Daines, B.K.; Dennis, D.A. Management of bone defects in revision total knee arthroplasty. *J. Bone Jt. Surg. Am.* 2012, 94, 1131–1139. [CrossRef] [PubMed]

124. Pivec, R.; Naziri, Q.; Issa, K.; Banerjee, S.; Mont, M.A. Systematic review comparing static and articulating spacers used for revision of infected total knee arthroplasty. *J. Arthroplast.* 2014, 29, 553–557. [CrossRef]